Abstract: HJ Science, an autoimmune, metabolic and oncology drug developer, launched its Hong Kong IPO to raise USD143m. In this note, we look at the deal terms and recap our valuation thoughts for the company. We also look at the main reason that caps the return of the deal.
B&K CORP LTD -H (2396 HK)LBC HK (LBC HK)
Highlighted Stocks
B&K CORP LTD -H, LBC HK
About ECM & IPO Research
Research on Hong Kong and A+H equity offerings, from the first filing to the aftermarket. Coverage includes pre-IPO early thoughts on the business and valuation, analysis of the final deal terms and cornerstone investors, and updates as new prospectus versions are filed.
